Do SGLT2 inhibitors reduce circadian blood pressure in hypertensive patients with diabetes?
SGLT2 inhibitors provide modest, consistent blood pressure reductions in diabetic hypertensive patients regardless of dose or specific agent, supporting their use as adjunctive therapy.
SGLT2 inhibitors produced modest and consistent reductions in BP, with no evidence of dose-dependence or meaningful differences among agents. Safety events were not credibly increased. These findings support their use as adjunctive therapy in patients with diabetes and hypertension.
Semirani-Nezhad et al. (Thu,) studied this question.